Iman Zaky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Iman Zaky has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed El Ghoneimy
Children Cancer Hospital, Cairo, Egypt
1 shared publication - Ali Mostafa Anwar
Turku Bioscience Centre, University of Turku and Åbo Akademi University , Turku 20520
1 shared publication - Manal Zamzam
Pediatric Oncology Department, Children’s Cancer Hospital Egypt 57357, Cairo 11441, Egypt
1 shared publication - Maram Alaa
Immunology and Microbiology Research Program, Basic Research Unit, Research Department, Children’s Cancer Hospital Egypt 57357, Cairo 11441, Egypt
1 shared publication - Mustafa Shaban Shawky
Pathology Department, Children’s Cancer Hospital Egypt 57357, Cairo 11441, Egypt
1 shared publication - Nesma Farid
Clinical Research Unit, Research Department, Children’s Cancer Hospital Egypt 57357, Cairo 11441, Egypt
1 shared publication
Latest Publications
- Open Access
Comparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes
Osteosarcoma is a primary malignant bone tumor affecting adolescents and young adults. This study aimed to identify proteomic signatures that distinguish between different osteosarcoma subtypes, providing insights into their molecular heterogeneity and potential implications for personalized treatment approaches. Using advanced proteomic techniques, we analyzed FFPE tumor samples from a cohort of pediatric osteosarcoma patients representing four various subtypes. Differential expression analysis revealed a significant proteomic signature that discriminated between these subtypes, highlighting distinct molecular profiles associated with different tumor characteristics. In contrast, clinical determinants did not correlate with the proteome signature of pediatric osteosarcoma. The identified proteomics signature encompassed a diverse array of proteins involved in focal adhesion, ECM-receptor interaction, PI3K-Akt signaling pathways, and proteoglycans in cancer, among the top enriched pathways. These findings underscore the importance of considering the molecular heterogeneity of osteosarcoma during diagnosis or even when developing personalized treatment strategies. By identifying subtype-specific proteomics signatures, clinicians may be able to tailor therapy regimens to individual patients, optimizing treatment efficacy and minimizing adverse effects.
Open AccessComparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes
Osteosarcoma is a primary malignant bone tumor affecting adolescents and young adults. This study aimed to identify proteomic signatures that distinguish between different osteosarcoma subtypes, providing insights into their molecular heterogeneity and potential implications for personalized treatment approaches. Using advanced proteomic techniques, we analyzed FFPE tumor samples from a cohort of pediatric osteosarcoma patients representing four various subtypes. Differential expression analysis revealed a significant proteomic signature that discriminated between these subtypes, highlighting distinct molecular profiles associated with different tumor characteristics. In contrast, clinical determinants did not correlate with the proteome signature of pediatric osteosarcoma. The identified proteomics signature encompassed a diverse array of proteins involved in focal adhesion, ECM-receptor interaction, PI3K-Akt signaling pathways, and proteoglycans in cancer, among the top enriched pathways. These findings underscore the importance of considering the molecular heterogeneity of osteosarcoma during diagnosis or even when developing personalized treatment strategies. By identifying subtype-specific proteomics signatures, clinicians may be able to tailor therapy regimens to individual patients, optimizing treatment efficacy and minimizing adverse effects.